Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Share-based Compensation (2021 - 2025)

Historic Share-based Compensation for InMed Pharmaceuticals (INM) over the last 5 years, with Q4 2025 value amounting to $25564.0.

  • InMed Pharmaceuticals' Share-based Compensation rose 1038.47% to $25564.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $112952.0, marking a year-over-year decrease of 2283.75%. This contributed to the annual value of $119307.0 for FY2025, which is 1336.61% down from last year.
  • According to the latest figures from Q4 2025, InMed Pharmaceuticals' Share-based Compensation is $25564.0, which was up 1038.47% from $20205.0 recorded in Q3 2025.
  • Over the past 5 years, InMed Pharmaceuticals' Share-based Compensation peaked at $214779.0 during Q4 2021, and registered a low of $18264.0 during Q4 2023.
  • Its 5-year average for Share-based Compensation is $71046.6, with a median of $40467.0 in 2023.
  • In the last 5 years, InMed Pharmaceuticals' Share-based Compensation tumbled by 7841.04% in 2023 and then surged by 2680.14% in 2024.
  • Quarter analysis of 5 years shows InMed Pharmaceuticals' Share-based Compensation stood at $214779.0 in 2021, then crashed by 67.11% to $70638.0 in 2022, then crashed by 74.14% to $18264.0 in 2023, then increased by 26.8% to $23159.0 in 2024, then increased by 10.38% to $25564.0 in 2025.
  • Its last three reported values are $25564.0 in Q4 2025, $20205.0 for Q3 2025, and $26729.0 during Q2 2025.